Literature DB >> 20812851

Interferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis.

Timothy Lahey1, Siddharth Sheth, Mecky Matee, Robert Arbeit, C Robert Horsburgh, Lillian Mtei, Todd Mackenzie, Muhammad Bakari, Jenni M Vuola, Kisali Pallangyo, C Fordham von Reyn.   

Abstract

BACKGROUND: The cellular immune responses that protect against tuberculosis have not been identified.
METHODS: We assessed baseline interferon γ (IFN‐γ) and lymphocyte proliferation assay (LPA) responses to antigen 85 (Ag85), early secretory antigenic target 6 (ESAT‐6), and Mycobacterium tuberculosis whole cell lysate (WCL) in human immunodeficiency virus (HIV)-infected and bacille Calmette‐Guérin (BCG)-immunized adults with CD4 cell counts of >or= 200 cells/μL who received placebo in the DarDar tuberculosis vaccine trial in Tanzania. Subjects were followed prospectively to diagnose definite or probable tuberculosis.
RESULTS: Tuberculosis was diagnosed in 92 of 979 subjects during a mean follow‐up of 3.2 years. The relative risk of tuberculosis among subjects with positive IFN‐γ responses to Ag85 was 0.51 (95% confidence interval [CI], 0.26-0.99; P = .049), to ESAT‐6 was 0.44 (95% CI, 0.23-0.85; P = .004), and to WCL was 0.67 (95% CI, 0.49-0.88; P = .002). The relative risk of tuberculosis was not significantly associated with baseline LPA responses. In a multivariate Cox regression model, subjects with IFN‐γ responses to ESAT‐6 and WCL had a lower hazard of developing tuberculosis, with a hazard ratio for ESAT‐6 of 0.35 (95% CI, 0.16–0.77; P = .009) and a hazard ratio for WCL of 0.30 (95% CI, 0.16-0.56; P < .001).
CONCLUSIONS: Baseline IFN‐γ responses to ESAT-6 and WCL were associated with protection from subsequent tuberculosis among HIV-infected subjects with childhood BCG immunization in a region of high tuberculosis prevalence. Trial registration. ClinicalTrials.gov identifier: NCT00052195.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20812851      PMCID: PMC2941548          DOI: 10.1086/656332

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  46 in total

1.  Molecular and conventional epidemiology of Mycobacterium tuberculosis in Botswana: a population-based prospective study of 301 pulmonary tuberculosis patients.

Authors:  S Lockman; J D Sheppard; C R Braden; M J Mwasekaga; C L Woodley; T A Kenyon; N J Binkin; M Steinman; F Montsho; M Kesupile-Reed; C Hirschfeldt; M Notha; T Moeti; J W Tappero
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

2.  Cellular immune responses to four doses of percutaneous bacille Calmette-Guérin in healthy adults.

Authors:  P W Lowry; T S Ludwig; J A Adams; M L Fitzpatrick; S M Grant; G A Andrle; M R Offerdahl; S N Cho; D R Jacobs
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

3.  Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis.

Authors:  R D Waddell; C Chintu; A D Lein; A Zumla; M R Karagas; K S Baboo; J D Habbema; A N Tosteson; P Morin; S Tvaroha; R D Arbeit; A Mwinga; C F von Reyn
Journal:  Clin Infect Dis       Date:  2000-06       Impact factor: 9.079

4.  The effects of BCG immunization and human immunodeficiency virus infection on dual skin test reactions to purified protein derivative and Mycobacterium avium sensitin among adults in Zambia.

Authors:  R D Waddell; C F von Reyn; K S Baboo; A Mwinga; C Chintu; A Zumla
Journal:  Int J Tuberc Lung Dis       Date:  1999-03       Impact factor: 2.373

5.  The immune response to Mycobacterium tuberculosis in HIV-infected and uninfected adults in Uganda: application of a whole blood cytokine assay in an epidemiological study.

Authors:  A M Elliott; T J Hurst; M N Balyeku; M A Quigley; P Kaleebu; N French; B Biryahwaho; J A Whitworth; H M Dockrell; R J Hayes
Journal:  Int J Tuberc Lung Dis       Date:  1999-03       Impact factor: 2.373

6.  Skin test reactions to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States.

Authors:  C F von Reyn; C R Horsburgh; K N Olivier; P F Barnes; R Waddell; C Warren; S Tvaroha; A S Jaeger; A D Lein; L N Alexander; D J Weber; A N Tosteson
Journal:  Int J Tuberc Lung Dis       Date:  2001-12       Impact factor: 2.373

7.  BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies.

Authors:  Gillian F Black; Rosemary E Weir; Sian Floyd; Lyn Bliss; David K Warndorff; Amelia C Crampin; Bagrey Ngwira; Lifted Sichali; Bernadette Nazareth; Jenefer M Blackwell; Keith Branson; Steven D Chaguluka; Linda Donovan; Elizabeth Jarman; Elizabeth King; Paul E M Fine; Hazel M Dockrell
Journal:  Lancet       Date:  2002-04-20       Impact factor: 79.321

8.  Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial.

Authors:  Jenni M Vuola; Matti A Ristola; Bernard Cole; Annika Järviluoma; Susan Tvaroha; Terhi Rönkkö; Outi Rautio; Robert D Arbeit; C Fordham von Reyn
Journal:  AIDS       Date:  2003-11-07       Impact factor: 4.177

9.  Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy.

Authors:  Stefania Carrara; Donatella Vincenti; Nicola Petrosillo; Massimo Amicosante; Enrico Girardi; Delia Goletti
Journal:  Clin Infect Dis       Date:  2004-02-17       Impact factor: 9.079

10.  Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis.

Authors:  Katalin A Wilkinson; Ronnett Seldon; Graeme Meintjes; Molebogeng X Rangaka; Willem A Hanekom; Gary Maartens; Robert J Wilkinson
Journal:  Am J Respir Crit Care Med       Date:  2009-07-23       Impact factor: 21.405

View more
  13 in total

1.  Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania.

Authors:  Timothy Lahey; Robert D Arbeit; Muhammad Bakari; C Robert Horsburgh; Mecky Matee; Richard Waddell; Lillian Mtei; Jenni M Vuola; Kisali Pallangyo; C Fordham von Reyn
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

2.  Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis.

Authors:  Timothy Lahey; Todd Mackenzie; Robert D Arbeit; Muhammad Bakari; Lillian Mtei; Mecky Matee; Isaac Maro; C Robert Horsburgh; Kisali Pallangyo; C Fordham von Reyn
Journal:  Clin Infect Dis       Date:  2012-09-12       Impact factor: 9.079

3.  The Use of Interferon-γ Release Assays for Tuberculosis Screening in International Travelers.

Authors:  Ludwig Apers; Cédric Yansouni; Patrick Soentjens; Marc Vekemans; Emmanuel Bottieau
Journal:  Curr Infect Dis Rep       Date:  2011-06       Impact factor: 3.725

4.  Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosis.

Authors:  Shruthi Ravimohan; Neo Tamuhla; Andrew P Steenhoff; Rona Letlhogile; Didimalang Kgomotso Makutu; Kebatshabile Nfanyana; Tumelo Rantleru; Ann Tierney; Kelebogile Nkakana; Adam B Schwartz; Robert Gross; Rob Roy Macgregor; Scarlett L Bellamy; Ian Frank; Drew Weissman; Gregory P Bisson
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

5.  Greater preexisting interferon γ responses to mycobacterial antigens and lower bacillary load during HIV-associated tuberculosis.

Authors:  Timothy Lahey; Tom Czechura; Scott Crabtree; Robert D Arbeit; Mecky Matee; C Robert Horsburgh; Todd MacKenzie; Muhammad Bakari; Kisali Pallangyo; C Fordham von Reyn
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

6.  Differences in antigen-specific CD4+ responses to opportunistic infections in HIV infection.

Authors:  Katrina M Pollock; Damien J Montamat-Sicotte; Graham S Cooke; Moses S Kapembwa; Onn M Kon; Lisa Grass; Robert D Sampson; Graham P Taylor; Ajit Lalvani
Journal:  Immun Inflamm Dis       Date:  2015-04-29

7.  Asymptomatic HIV-infected individuals on antiretroviral therapy exhibit impaired lung CD4(+) T-cell responses to mycobacteria.

Authors:  Kondwani C Jambo; Dominic H Banda; Louise Afran; Anstead M Kankwatira; Rose D Malamba; Theresa J Allain; Stephen B Gordon; Robert S Heyderman; David G Russell; Henry C Mwandumba
Journal:  Am J Respir Crit Care Med       Date:  2014-10-15       Impact factor: 21.405

8.  Pulmonary immune-compartment-specific interferon gamma responses in HIV-infected individuals with active tuberculosis (TB) in an area of high TB prevalence.

Authors:  S Buldeo; D M Murdoch; M S Suchard
Journal:  Clin Dev Immunol       Date:  2012-06-21

9.  Polyantigenic interferon-γ responses are associated with protection from TB among HIV-infected adults with childhood BCG immunization.

Authors:  Timothy Lahey; Brian K Mitchell; Robert D Arbeit; Siddharth Sheth; Mecky Matee; C Robert Horsburgh; Todd MacKenzie; Lillian Mtei; Muhammad Bakari; Jenni M Vuola; Kisali Pallangyo; C Fordham von Reyn
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240

10.  Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV.

Authors:  Adriana Weinberg; Lisa Aaron; Grace Montepiedra; Timothy R Sterling; Renee Browning; Blandina Mmbaga; Tichaona Vhembo; Shilpa Naik; Enid Kabugho; Gaerolwe Masheto; Savita Pahwa; Jyoti S Mathad; Sylvia M LaCourse; Katie McCarthy; Sarah Bradford; Gerhard Theron; Diane Costello; Bonnie Zimmer; Marie F Pierre; Kamunkhwala Gausi; Paolo Denti; David W Haas; Amita Gupta
Journal:  Clin Infect Dis       Date:  2021-11-02       Impact factor: 20.999

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.